Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo

• Autors principals: Zi'ang Xie (Autor), Guanxiong Liu (Autor), Pan Tang (Autor), Xuewu Sun (Autor), Shuai Chen (Autor), An Qin (Autor), Peizhi Zhu (Autor), Jianfeng Zhang (Autor), Shunwu Fan (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Rheumatoid arthritis (RA), a disease that causes joint destruction and bone erosion, is related to osteoclast activity. RA is generally treated with methotrexate (MTX). In this study, a MTX-Alendronate (ALN) conjugate was synthesized and characterized. The conjugate dramatically inhibited osteoclast...